Skip to main content
. 2017 Dec 1;1(1):13. doi: 10.1186/s41824-017-0018-7

Fig. 2.

Fig. 2

PET/CT with 18F–FDG and 18F–FCh in low-differentiated hepatocellular carcinoma. Patient (a). Low-differentiated hepatocellular carcinoma. Images of axial projections of PET (a, c) and combined images of PET/CT (b, d) with 18F–FDG (a, b) and with 18F–FCh (c, d). With PET/CT with 18F–FDG in the right lobe of the liver, the focus of pathological accumulation of the radiopharmaceutical agent (red arrows) is visualized. With PET/CT with 18F–FCh, the pathological accumulation of 18F–FCh in the liver is not determined